Affinity Asset Advisors LLC Purchases Shares of 250,000 Puma Biotechnology, Inc. (NASDAQ:PBYI)

Affinity Asset Advisors LLC purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $815,000. Affinity Asset Advisors LLC owned about 0.51% of Puma Biotechnology as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Puma Biotechnology during the first quarter valued at approximately $57,000. Victory Capital Management Inc. purchased a new stake in Puma Biotechnology in the second quarter worth about $54,000. Crestline Management LP increased its position in Puma Biotechnology by 6.5% in the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 2,135 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Puma Biotechnology by 5,129.0% in the first quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 48,520 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 48,184 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $2.55 on Wednesday. Puma Biotechnology, Inc. has a 12 month low of $2.13 and a 12 month high of $7.73. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 0.90. The stock has a market cap of $125.08 million, a PE ratio of 7.73 and a beta of 1.09. The stock’s 50 day moving average is $3.00 and its 200 day moving average is $3.88.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same quarter in the prior year, the business earned $0.05 earnings per share. Research analysts predict that Puma Biotechnology, Inc. will post 0.25 EPS for the current fiscal year.

Insider Activity

In related news, CEO Alan H. Auerbach sold 21,920 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the transaction, the chief executive officer now directly owns 7,063,515 shares of the company’s stock, valued at $26,135,005.50. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Alan H. Auerbach sold 21,920 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the transaction, the chief executive officer now directly owns 7,063,515 shares in the company, valued at approximately $26,135,005.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the transaction, the director now directly owns 47,000 shares of the company’s stock, valued at $164,030. The disclosure for this sale can be found here. Insiders sold a total of 82,263 shares of company stock worth $286,469 over the last 90 days. Corporate insiders own 23.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on PBYI shares. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Friday, August 2nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.